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Developing Appropriate Methods for
Cost-Effectiveness Analysis of Cluster
Randomized Trials
Manuel Gomes, MSc, Edmond S.-W. Ng, MSc, Richard Grieve, PhD, Richard
Nixon, PhD, James Carpenter, PhD, Simon G. Thompson, DSc
Aim. Cost-effectiveness analyses (CEAs) may use data from
cluster randomized trials (CRTs), where the unit of random-
ization is the cluster, not the individual. However, most stud-
ies use analytical methods that ignore clustering. This article
compares alternative statistical methods for accommodating
clustering in CEAs of CRTs. Methods. Our simulation study
compared the performance of statistical methods for CEAs of
CRTs with 2 treatment arms. The study considered a method
that ignored clustering—seemingly unrelated regression
(SUR) without a robust standard error (SE)—and 4 methods
that recognized clustering—SUR and generalized estimating
equations (GEEs), both with robust SE, a ‘‘2-stage’’ nonpara-
metric bootstrap (TSB) with shrinkage correction, and a mul-
tilevel model (MLM). The base case assumed CRTs with
moderate numbers of balanced clusters (20 per arm) and
normally distributed costs. Other scenarios included CRTs
with few clusters, imbalanced cluster sizes, and skewed
costs. Performance was reported as bias, root mean squared
error (rMSE), and confidence interval (CI) coverage for esti-
mating incremental net benefits (INBs). We also compared
the methods in a case study. Results. Each method reported
low levels of bias. Without the robust SE, SUR gave poor CI
coverage (base case: 0.89 v. nominal level: 0.95). The MLM
and TSB performed well in each scenario (CI coverage,
0.92–0.95). With few clusters, the GEE and SUR (with robust
SE) had coverage below 0.90. In the case study, the mean
INBs were similar across all methods, but ignoring clustering
underestimated statistical uncertainty and the value of fur-
ther research. Conclusions. MLMs and the TSB are appropri-
ate analytical methods for CEAs of CRTs with the
characteristics described. SUR and GEE are not recommen-
ded for studies with few clusters. Key words: randomized
trial methodology; statistical methods; cost-effectiveness
analysis. (Med Decis Making 2012;32:350–361)
Cost-effectiveness analyses (CEAs) of group-basedinterventions often use data from cluster ran-
domized trials (CRTs).1 A cluster design may be pre-
ferred in evaluations of interventions, which operate
at a group level (e.g., alternative incentives for
health providers), or where there is a high risk of
‘‘contamination’’ among the individuals within
clusters (e.g., vaccination programs).2,3 Agencies
such as the National Institute for Health and Clinical
Excellence may use these CEAs especially when re-
commending which public health interventions
should be provided.4 For these studies to provide
a sound basis for decision making, appropriate sta-
tistical methods need to be developed and used.5,6
CEAs based on randomized controlled trials (RCTs),
where individual patients are randomized, have
well-established methods.7–9 However, statistical
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methods for CEAs of CRTs have received limited
attention.10 A review found that less than 10% of
published CEAs of CRTs adopted appropriate statis-
tical methods.1
A distinct feature of CRTs is that the unit of ran-
domization is the cluster (e.g., the hospital), not the
patient. Each patient within a cluster is randomized
to receive the same treatment, and so the form of clus-
tering differs from multicenter RCTs, where patients
within a center are randomized to different treat-
ments. In CRTs, individuals within a cluster are
likely to be somewhat similar in their characteristics
and the care they receive, and therefore, individual
outcomes or costs within the same cluster tend to
be more homogeneous than those in different clus-
ters. The extent of such clustering can be summarized
by the intracluster correlation coefficient (ICC),
which reports the proportion of the overall variation
that is at the cluster level. For the analysis of clinical
outcomes, it is recognized that ignoring clustering
underestimates statistical uncertainty,2,3,11 encour-
ages incorrect inferences,12–15 and can also lead to
bias.16,17 Appropriate methods for handling cluster-
ing in clinical outcomes are well developed and can
include multilevel models (MLMs) and generalized
estimating equations (GEEs).18
CEAs of CRTs raise additional challenges for sta-
tistical methods. Here, methods are required that not
only allow for clustering but also acknowledge the
correlation between individual costs and out-
comes19–21 and make plausible assumptions about
the distribution of costs and outcomes. Based on
a conceptual review, we identified 4 main groups
of statistical methods that may be appropriate for
CEAs of CRTs: seemingly unrelated regression
(SUR),21 GEEs,22 the nonparametric 2-stage boot-
strap (TSB),23 and MLMs.20 Each of these methods
can accommodate both clustering and correlation
in a bivariate approach. We did not consider univar-
iate net benefit regression analysis, as this method
has less flexibility: for example, it does not allow
for separate distributional assumptions to be made
for costs (which tend to be highly skewed) as
opposed to outcomes.
There is limited evidence comparing these alterna-
tive statistical methods for CEAs of CRTs. The TSB24
and MLMs25 have been proposed for CEAs of CRTs,
but the only study26 to compare these methods used
data from a single CRT. A simulation study24 assessed
the performance of the TSB but did not compare it to
MLMs or GEEs and assumed balanced clusters (equal
numbers per cluster). It is therefore unclear which
method performs best across the range of circumstan-
ces faced in CEAs of CRTs.
The aim of this article was to assess the relative
performance of alternative statistical methods for
CEAs of 2-arm CRTs. We address this by conducting
an extensive simulation study and illustrate the prac-
tical use of the methods in a case study. In the next
section, we describe each analytical method, the
design of the Monte Carlo simulations, and the case
study. We then present the results of the simulations
and case study. The last section discusses the key
findings and outlines an agenda for further research.
METHODS
Statistical Methods for CEAs of CRTs
We consider 4 methods for CEAs that use CRT
data. We use the following notation: let cij and eij
represent the costs and outcomes for the ith individ-
ual in the jth cluster. For simplicity, the models and
the simulation study are described for CEAs with 2
alternative treatments, but the models extend to
evaluations with more than 2 randomized treat-
ments. Each method takes the common approach
of assuming linear additive treatment effects for
both costs and outcomes.9,20,21,27
Seemingly Unrelated Regression (SUR)
SUR consists of a system of regression equations
that can recognize the correlation between individ-
ual costs and outcomes.9,10,21 The SUR model1
allows the individual-level error terms (e) to be cor-
related through the parameter r:
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where tj is the treatment indicator (tj = 0 for con-
trol and 1 for treatment group). The parameters of
interest, the incremental costs (bc1) and outcomes
(be1), can be estimated by ordinary least squares
(OLS). SUR assumes the individual error terms (e)
have a bivariate normal distribution (BVN), with var-
iances s2c and s
2
e . Conceptually, SUR can be extended
to accommodate clustering by including random
effects,28 but this cannot be readily implemented in
STATISTICAL METHODS FOR CEA OF CLUSTER TRIALS
ORIGINAL ARTICLES 351
conventional software packages. A practical way of
allowing the uncertainty estimates to reflect cluster-
ing is to report robust SE by iterative feasible general-
ized nonlinear least squares (IFGNLS) (nlsur package,
STATA 11, StataCorp, College Station, TX). Estimates
are identical to OLS when the same covariates are
included for costs and outcomes.21,a
A limitation of SUR is that its implementation in
most standard statistical packages assumes the errors
are normally distributed, which may not be plausible
in the context of CEAs of CRTs. In addition, it is
unclear whether the robust SE recognizes the correla-
tion at the cluster level, that is, between cluster-level
mean costs and mean outcomes.29,30 Finally, the
asymptotic assumptions underlying the robust vari-
ance estimator may not hold in CRTs with few clus-
ters per treatment arm.31 The problem can be
exacerbated by skewed outcomes (or costs) or imbal-
anced cluster sizes.18 More details on the robust var-
iance estimator are given in Web Appendix 1.
Generalized Estimating Equations (GEEs)
A similar approach for handling clustering is to
use a GEE model with robust SE. In general, GEEs
offer a flexible extension of likelihood-based gener-
alized linear models and are commonly used to ana-
lyze clinical outcomes in CRTs.2,3,32 While
multivariate GEEs have been developed to recognize
potential correlation between binary end points,22
they are complex to implement and have not been
extended to continuous end points. As a practical
alternative, we used a GEE model with independent
estimating equations, stacking costs and outcomes,
into a single vector but still allowing separate, inde-
pendent estimates of incremental costs and out-
comes. A bivariate GEE model with independent
estimating equations can be written as:
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This structure relies on a general property of pop-
ulation-averaged GEEs, ensuring asymptotically
consistent regression parameter estimates, even if
the working correlation matrix is misspecified.
This holds as long as the model, that is, the relation-
ship between the marginal mean and the linear predic-
tor, is correct. However, if the working correlation
matrix is misspecified, the parameter estimates may
be less statistically efficient.
Parameter estimates can be obtained by maximum
likelihood, assuming that the errors have normal dis-
tributions, and can provide the same point estimates
to OLS estimation. As with SUR, we assumed that the
error terms have a bivariate normal distribution,
although the model could be extended to allow for
other distributions. We have used a robust estimator
for the variance to allow for clustering when report-
ing uncertainty: see Web Appendix 1 for further
details. However, the asymptotic properties required
may not hold when there are few clusters.13,15,33,65-68
The Nonparametric 2-Stage Bootstrap (TSB)
Nonparametric bootstrap methods can avoid
parametric assumptions and are easy to apply in
simple settings (e.g., RCTs).19 However, the con-
ventional nonparametric bootstrap that resamples
individuals has to be extended to recognize the
clustering inherent in CRTs. Davison and Hinkley23
propose a 2-stage routine for CRTs, which resam-
ples clusters as well as individuals, and this
approach has been considered for CEAs.24,26,34
The TSB can recognize the individual-level correla-
tion between costs and outcomes by bivariate
resampling, and the resampling can also stratify
by treatment group.24
TSB without shrinkage correction. One proposed
TSB algorithm requires resampling clusters and then
individuals within each resampled cluster (both with
replacement).23 The resultant data sets are used to cal-
culate the statistics of interest, for example, incremen-
tal net benefits (INBs) and confidence intervals (CIs).
However, unless the CRT has many clusters and indi-
viduals per cluster, this routine can overestimate the
variance. Resampling at the second stage is likely to
double count the within-cluster variance because the
estimated cluster means from resampling at the first
stage already incorporate both within- and between-
cluster variability.23,24,34
TSB with shrinkage correction. Davison and Hink-
ley23 recommend a ‘‘shrinkage estimator’’ to correct for
possible overestimation of the variance. Here, before
any resampling, cluster means are calculated with
a shrinkage correction and individual-level residuals
estimated from the cluster means. Two-stage resam-
pling (with replacement) is then performed by firstly
resampling the shrunken cluster means and secondly
resampling the standardized individual-level resid-
uals across all clusters. Bootstrap data sets are
a. Where different covariates are included for costs and outcomes, SUR estimation
by IFGNLS can improve statistical efficiency (precision) compared to OLS.
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compiled by combining the resampled shrunken clus-
ter means and individual-level residuals. Unlike the
previous routine where clusters and individuals are
resampled from the original data, this routine resam-
ples the shrunken means and residuals: see Web
Appendix 2 for more details about the algorithms.
Both bootstrap routines rely on asymptotic
assumptions, and it is unclear whether they are
satisfied with few clusters, particularly if data
are nonnormal.35,36 Furthermore, the TSB routines
described above were only proposed for balanced
clusters,23,24,34 which may make the method inap-
propriate for CEAs of CRTs with imbalanced clusters.1
Our implementation therefore extends Davison and
Hinkley’s original algorithms to allow for imbalanced
clusters (Web Appendix 2).
Multilevel Models (MLMs)
MLMs can allow for the correlation between costs
and outcomes and recognize clustering.25 Unlike
SUR, MLMs can explicitly recognize clustering by
including additional random terms, ucj ;u
e
j , which
in equation 3 below represent the differences in
the cluster mean costs and outcomes from the over-
all means in each treatment group. These random
effects are assumed to follow a bivariate normal dis-
tribution, with variances t2c and t
2
e . MLMs acknowl-
edge individual- and cluster-level correlation
between costs and outcomes through the parameters
r and c. The coefficients bc1 and b
e
1 still represent
incremental costs and outcomes after allowing for
clustering. Like the SUR model, this particular
MLM assumes that the individual error terms (e)
are normally distributed, but more generally, alter-
native distribution assumptions can be made for
costs, outcomes, or both.
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MLMs can be estimated and interpreted from a fre-
quentist perspective, generally implemented with
maximum likelihood or with a Bayesian approach
typically using Markov chain Monte Carlo (MCMC)
methods. Current software options for MCMC esti-
mation afford a wide choice of distributional
assumptions.20 A concern with either approach is
that the MLM may fail to converge if the CRT has
few individuals per cluster.37,38
Monte Carlo Simulations
Data-generating process. The simulation study was
designed to test the methods across a wide range of cir-
cumstances typically found in CEAs of CRTs. Our con-
ceptual review suggested it was important to allow the
following to differ: number of clusters per treatment
arm, number of individuals per cluster, level of cluster
size imbalance, ICCs, skewness in the cost distribu-
tion, and correlation between costs and outcomes at
both the individual and cluster level (see rationale in
Table 1). To consider this range of settings required
a flexible data-generating process. Data were con-
structed to reflect the specific form of clustering found
in CRTs.12,37,39 The design allowed for a wide range of
parameters to be varied and could accommodate dif-
ferent parametric distributions for costs and outcomes.
As in previous simulation studies in economic evalu-
ation, we assumed a linear additive treatment effect
throughout.21,24,40 We simulated cost (c) and outcome
data (e) from CRTs with M clusters per arm and nm
(m = 1. . .M) individuals per cluster. Data were gener-
ated firstly at the cluster level and then at the individ-
ual level according to equation 4 below.
Cluster level means:
fcj;distðbc01bc1tj; tcÞ
cij;distðfj;sjcÞ
Individual-level data:
fej;distðbe01be11 gðfcj  ðbc01bc1tjÞÞ; teÞ
eij;distðfj1 u1ðcij  fcj Þ;seÞ:
ð4Þ
Cluster-level mean costs (fcj ) and outcomes (f
e
j )
were simulated for the jth cluster. These were
assumed to follow a certain distribution charac-
terized by the cluster means for the control
ðbc0;be01gðfcj2bc0ÞÞ and treatment ðbc01bc1;be01
be11 gðjcj2ðbc01bc1tjÞÞÞ groups and the correspond-
ing cluster-level standard deviations ðtc; teÞ. This
mechanism allowed costs and outcomes to be corre-
lated at the cluster level through the parameter g,
where g5cðte=tcÞ. Costs (cij) and outcomes (eij) for
the ith individual were simulated from distributions
centered at the previously simulated cluster-level
means and with the corresponding individual-level
standard deviations (sc;se). Costs and outcomes
were also allowed to be correlated at the individual
level through the term u, where u = r(se/sc). ICCs
were set to recognize the proportion of the total vari-
ance at the cluster level, for example, for costs
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Table 1 Description, Rationale, and Evidence for the Parameter Values Allowed to Vary across the Different
Scenarios
Parameter Rationale Base Case SA Final Case Justification for Parameter Levels
No. of clusters
per arm
GEE, SUR, and TSB all
rely on asymptotic
assumptions
20 3 to 30 15 Base case: 20 clusters per arm
suggested for asymptotics to
hold.2,61 SA: takes lower, upper
quartiles from literature review.
Final case: median number of
clusters from literature review.
No. of individuals per
cluster
MLM may have
convergence issues
with few cases per
cluster
50 10 to 80 30 Base case: within the range of
values from literature review. SA:
the lower, upper quartiles from
literature review. Final case:
median number per cluster from
the literature review.
Level of
imbalance(cvimb) of
cluster size
GEE, SUR, and TSB
have not been
assessed with
imbalanced clusters
0 0 to 1 0.5 Base case: previous methods
articles.23,24,34 SA: cluster-size
imbalance informed by range of
values reported across case
studies and previous study.42
Final case: median from the case
studies.
ICC for costs To assess if methods
can handle high
levels of clustering
0.01 0 to 0.3 0.05 Base case: Start with low ICC as
per previous methods
articles.24,34 SA: range of ICCs
from case studies and previous
study.62 Final case: median from
case studies.
ICC for outcomes As above 0.01 0 to 0.3 0.02 Base case: 30% of studies from
literature review have ICCs for
outcomes 0.01. SA: range from
literature review and previous
methods studies.42 Final case:
median from literature review.
Coefficient of
variation(cvcost) of
cost distribution
SUR, MLM, and GEE
assume errors follow
a normal distribution
0.2 0.25 to 3 0.5 Base case: start with normal
distribution; no skewness as per
previous simulation studies.36,63
SA: g distribution; range for cvcost
from previous simulation
studies.41,43 Final case: gamma
distribution; median cvcost from
case studies.
Individual-level
correlation of costs
and effects
GEE assumes costs and
outcomes are
independent
0.2 20.5 to 0.5 20.2 Base case: plausible level of
individual-level
correlation.24,43SA: based on the
range from case studies. Final
case: median from the case
studies.
Cluster-level
correlation of costs
and effects
GEE as above; SUR
ignores cluster-level
correlation
0 20.5 to 0.5 0.1 Base case: conservative value
assuming no correlation at the
cluster level.24 SA: based on the
range from case studies. Final
case: median from case studies.
Note: SA = sensitivity analyses; ICC = intracluster correlation coefficient; GEE = generalized estimating equation; SUR = seemingly unrelated regres-
sion; TSB = nonparametric 2-stage bootstrap; MLM = multilevel model.
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ICCc5 t2c=ðs2c 1 t2c Þ. The size of the clusters was
assumed to follow a gamma distribution according to
a mean and a coefficient of variation (cvimb), which
is obtained by dividing the standard deviation of clus-
ter size by its mean; so for balanced (equal) cluster
sizes, cvimb = 0.
Definition of scenarios. The simulation study ini-
tially considered a base-case scenario, then 1-way
and multiway sensitivity analyses, and finished
with a final ‘‘most realistic’’ scenario. Under the
base-case scenario, parameter values were chosen
not only to be plausible but also to represent circum-
stances where each method was anticipated to per-
form well. This scenario provided a benchmark for
the subsequent sensitivity analyses (Table 1). The
choices of which parameters to vary in the sensitiv-
ity analyses, and which scenarios to combine in the
multiway sensitivity analyses, were informed by
general insights from the methods literature.
For each parameter, the range of values chosen
was grounded in a systematic literature review of
62 studies,1 previous methods articles and simula-
tion studies,24,41–43 and 8 case studies.44–51 In the
final scenario, each parameter was set to its ‘‘most
realistic’’ value, taking median values from the liter-
ature review and case studies. For example, costs
followed a normal distribution in the base case but
increasingly skewed gamma distributions in the sen-
sitivity analyses with coefficient of variation (cvcost)
ranging from 0.25 to 3.0 (final case, 0.5).
Table 1 lists the parameters changed across the sce-
narios; other parameters such as the true incremental
costs and outcomes (QALYs) were held constant
throughout. For example, the ‘‘true’’ incremental costs,
incremental QALYs, and INBs (assuming a threshold
of £20,000 per QALY) were £500, 0.075, and £1000,
respectively.
Implementation. The performance of the different
estimation methods was assessed according to mean
(SE) bias, root mean squared error (rMSE), CI cover-
age, the error rate for lower and upper CI limits, and
CI width (see Web Appendix 3 for definitions). We
used 2000 simulations for each scenario.b The per-
formance of each method in estimating incremental
costs, incremental QALYs, and INBs was reported.
MLM, GEE, and TSB were implemented in R52 and
SUR in STATA (StataCorp).53 The SUR was estimated
by IFGNLS, without and with a robust SE. The GEE
was estimated with a robust SE, and the TSB was esti-
mated before and then after shrinkage correction. The
MLM was estimated by maximum likelihood across
all scenarios.65 For selected scenarios (base case, 3
clusters per treatment, and the final case), estimation
was also carried out via MCMC by calling WinBUGS
from R.54 The MCMC estimation consisted of 5000
iterations, 3 parallel chains with different starting val-
ues, and assuming diffuse priors.55
Case Study
To consider the potential implications of the
choice of methods in practice, we compared the
methods in a case study of a CEA alongside a CRT.
This approach extends the simulation study as, for
example, the cost and outcome data do not follow
specified distributions; this allows for a more prag-
matic comparison of the methods. We compare esti-
mates of both relative cost-effectiveness and
potential value of further research across the meth-
ods. The potential value of further research is the
gain from resolving decision uncertainty, given the
current state of knowledge. In other words, the
expected value of perfect information (EVPI) is the
increase in net benefits from taking the optimal deci-
sion after resolving current uncertainty.56
The case study consists of a CRT that evaluates an
educational intervention intended to improve the
management of lung disease in adults attending out-
patient clinics in South Africa.46 The CRT included
40 balanced clusters (clinics) randomized to inter-
vention or control. This reanalysis used complete
data for 1851 patients. For each patient, the study
measured health service costs for 3 months, consist-
ing mainly of the costs of the educational interven-
tion clinic, outpatient visits, and drugs. EQ-5D
data were recorded at 3 months’ follow-up, and we
calculated QALYs, assuming that there was no mor-
tality. The ICCs for costs and outcomes were both
low (around 0.01). While the outcome data were
approximately normally distributed, the costs were
moderately skewed (cvcost = 1.6). Hence, the charac-
teristics of this study were fairly similar to those in
the base-case scenario in the simulation.
Each of the above statistical methods were used to
report incremental costs, QALYs, and INBs, calcu-
lated at realistic levels of the ceiling ratio for the
local South African context. We then used these
estimates across the alternative methods to compare
the EVPI per patient, as reported in other trial-based
CEAs.57,58 EVPI was calculated assuming that the
INB was normally distributed.56
b. This was judged to be sufficient to report CI coverage with a margin of MC error
of less than 1%; that is, for true coverage of 0.95, 2000 simulations would be 95% cer-
tain to give coverage rates of 0.94 to 0.96.
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RESULTS
Simulation Study
Base case. In the base case, each method reported
low bias and similar rMSE for the INB (Table 2). The
method that ignored clustering, SUR without the
robust SE, performed poorly with CI coverage below
0.9. The TSB without shrinkage correction reported
wide 95% CIs and coverage above the nominal level,
but with correction, coverage was similar to the
other methods that recognized clustering. The
MLM had coverage close to the nominal level
whether estimated by maximum likelihood (Table 2)
or MCMC (CI coverage, 0.94). The relative perfor-
mance across methods was similar for incremental
QALYs, incremental costs, and INBs calculated
with alternative levels of the ceiling ratio.
One-way sensitivity analysis. The bias was low
across all scenarios; for example, in the scenario
with 3 clusters per treatment arm, the mean (SE) biases
for the estimated INB were –9.98 (6.05) for SUR, –6.93
(6.28) for the MLM and GEE, and –7.15 (6.29) for the
TSB with shrinkage correction (true INB = £1000).
The rMSE differed across scenarios but was similar
for each method. For example, with 3 clusters per
arm, rMSE was about 280 for all methods.
Table 3 reports CI coverage for the 1-way sensitiv-
ity analyses. The bootstrap without correction
reported CI coverage above the nominal level for
most scenarios, but the other methods generally
reported good coverage, unless there were few clus-
ters. Here, CI coverage remained good for the MLM
and TSB (following correction), but the SUR and
GEE, both with robust SEs, reported poor coverage.
With high levels of cluster size imbalance, coverage
levels for these latter 2 methods were also low. All
the methods (except the TSB without correction)
performed well in scenarios with few individuals
per cluster, high ICCs, and highly skewed costs
(Table 3). CI coverage also remained close to the
nominal level, with high levels of correlation at the
individual or cluster level.
Multiway sensitivity analysis. The multiway sen-
sitivity analyses combined variation in the number
of clusters, levels of cluster size imbalance, and
cost skewness. Bias remained low (between –5 and
5) across all multiway sensitivity analyses. While
rMSE increased when fewer clusters were combined
with high levels of imbalance, the differences
between methods were small.
Figure 1 reports CI coverage for CRTs with
decreasing number of clusters (20, 15, 10, 8, 5, and
3 clusters per treatment arm), moderate and high
cluster-size imbalance (cvimb of 0.5 and 1), combined
with highly skewed costs (cvcost = 3). In CRTs with
moderate levels of imbalance, the performance of
SUR and GEE is worse than for the MLM and TSB
if there are 8 or fewer clusters per treatment arm
(Figure 1A). With high levels of cluster size imbal-
ance, the coverage levels for the SUR and GEE are
poor, with fewer than 10 clusters per arm (Figure
1B). For the MLM and TSB (with shrinkage correc-
tion), the CI coverage remains relatively good even
when the study has few highly imbalanced clusters
and highly skewed costs. In further scenarios that
combined variation in cluster-size imbalance and
number of clusters with other parameters, such as
different levels of individual- and cluster-level cor-
relation, all methods performed well except in sce-
narios with few clusters, where SUR and GEE
reported poor coverage.
Table 2 Bias, rMSE, CI Coverage, and Width of the Mean INB for the Base Case (True INB = £1000)
SUR
GEE
TSB
MLMaWithout
Robust SE
With
Robust SE
With
Robust SE
Without Shrinkage
Correction
With Shrinkage
Correction ML
Mean bias (SE) 21.999 (2.45) 21.999 (2.45) 21.999 (2.45) 22.108 (2.45) 22.041 (2.45) 21.999 (2.45)
rMSE 109.45 109.45 109.45 109.52 109.52 109.45
CI coverage 0.891 0.940 0.933 0.981 0.943 0.950
Mean CI width 353.6 423.7 417.7 539.1 427.5 440.7
Lower tail error rate 0.048 0.030 0.033 0.009 0.028 0.024
Upper tail error rate 0.051 0.029 0.035 0.011 0.030 0.026
Note: INB = incremental net benefit; SUR = seemingly unrelated regression; GEE = generalized estimating equation; TSB = nonparametric 2-stage boot-
strap; MLM = multilevel model; SE = standard error; ML = maximum likelihood; rMSE = root mean squared error; CI = confidence interval.
a. MLM estimated by Markov chain Monte Carlo (MCMC) in WinBUGS produced similar results.
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Final ‘‘most realistic’’ scenario. In the final sce-
nario with all parameters set to their ‘‘most realistic’’
levels (Table 1), bias and rMSE were again similar
across methods (Table 4). The SUR without a robust
SE and the TSB without correction reported levels of
CI coverage that diverged from the nominal, but the
MLM and TSB with correction both had good levels
of CI coverage.
Case Study
Table 5 presents cost-effectiveness results from
applying the alternative methods to the case study.
Each method reported that the intervention had
positive incremental costs, negative incremental
QALYs, and negative INBs. While the means were
similar across methods, applying SUR without
allowing for clustering led to standard errors
that were substantially smaller than for the other
methods. For SUR without the robust errors, the
EVPI (per patient) was more than 50% lower
when compared to methods that accommodate
clustering.
DISCUSSION
This study compares the relative merits of alter-
native statistical methods for CEAs of CRTs. The
simulation study finds that each method reports
low bias and similar MSE across the settings consid-
ered, with the MLM and TSB (with correction) pro-
viding good levels of CI coverage throughout. The
simulation study highlights that robust methods
(SUR and GEE), which rely on asymptotic assump-
tions, can perform poorly for studies with few clus-
ters. Both the simulation study and the case study
illustrate that methods that ignore clustering (e.g.,
SUR without a robust SE) can seriously underesti-
mate statistical uncertainty. As our empirical exam-
ple illustrates, ignoring clustering can therefore
understate the expected value of further research.
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Figure 1 CI coverage (nominal level is 0.95) for multiway sensi-
tivity analyses: high skewness of costs (cvcost = 3), decreasing
number of clusters combined with (A) moderate and (B)
high cluster-size imbalance. The CI coverage is very similar for
the GEE and SUR, and hence, their lines show considerable
overlap.
Table 3 Confidence Interval Coverage of the Mean Incremental Net Benefit (Nominal Level Is 0.95) for the 1-
Way Sensitivity Analyses
SUR GEE
TSB
MLMWith Robust
SE
With Robust
SE
Without Shrinkage
Correction
With Shrinkage
Correction ML
Base case 0.940 0.933 0.981 0.943 0.950
Few clusters per arm (M = 3) 0.856 0.841 0.962 0.941 0.933
Few individuals per cluster (nm = 10) 0.937 0.945 0.991 0.961 0.958
Highly imbalanced cluster size (cvimb=1) 0.919 0.916 0.981 0.960 0.951
High ICC for costs (ICCc = 0.3) 0.936 0.935 0.980 0.944 0.953
High ICC for outcomes (ICCe = 0.3) 0.941 0.941 0.941 0.943 0.945
Highly skewed g costs (cvcost = 3) 0.941 0.941 0.982 0.942 0.952
Note: SUR = seemingly unrelated regression; GEE = generalized estimating equation; TSB = nonparametric 2-stage bootstrap; MLM = multilevel model;
SE = standard error; ML = maximum likelihood; ICC = intracluster correlation coefficient.
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Future studies should not attempt to justify statisti-
cal methods that ignore clustering on the basis of
low estimated ICCs.
This is the first article to compare a range of statis-
tical methods for CEAs of CRTs. Previous simulation
studies24,34 did not consider MLMs or GEEs, and
other studies just compared the methods using a sin-
gle case study.26 The design of the simulation study
is sufficiently general to consider the methods
across common circumstances faced by CEAs of
CRTs. In particular, the simulation includes scenar-
ios with few clusters, unequal numbers per cluster
(imbalance), and highly skewed costs. The choice
of scenarios and parameters values are grounded in
a previous review of methods and of published
CEAs of CRTs.1 These features help ensure that the
simulation study provides relevant insights on the
choice of analytical method for future CEAs. While
for illustrative purposes we consider 2-armed
CRTs, the findings extend directly to CRTs with 3
or more randomized treatments.
The simulation study finds the TSB performs as
well as the MLM across the circumstances consid-
ered, once the shrinkage correction factor proposed
by Davison and Hinkley is applied. A previous
CEA used the TSB, but did not apply the shrinkage
correction, and reported wide CIs compared to
a MLM.26 We find that without the shrinkage correc-
tion, the TSB overstates the uncertainty, but once
the correction is applied, the method gives good
CI coverage. This finding contrasts with those of
a previous simulation study24 that only considered
balanced clusters but reported relatively poor perfor-
mance for the TSB (even after correction). We
extended the implementation to recognize cluster-
size imbalance and find that the method still
performs well. To help improve the translation of
appropriate methods into practice, we are developing
user-friendly software for implementing the TSB.
Sample codes for the TSB, GEE, and MLM are
included in Web Appendix 4.
This article considers GEEs for the first time in
this context. We develop a robust variance estimator
to account for the clustering that also allows for the
joint distribution of individual costs and outcomes.
A general concern for such a robust variance estima-
tor is that it relies on asymptotic assumptions,
which in these circumstances pertain to the number
of clusters per treatment arm. Our work provides
specific guidance for CEAs of CRTs on the number
of clusters per treatment arm required for asymptotic
assumptions to hold. Our findings suggest that
between 8 and 15 clusters per arm are required,
depending on the other features of the study; in par-
ticular, more clusters are required when the cluster
sizes are highly imbalanced. This is pertinent for
CEAs where about 40% of such studies have fewer
than 15 clusters per treatment arm and 15% less
than 8 clusters.1 The general literature on GEEs has
reported similar sample size requirements for
asymptotic assumptions to hold,13,15,18 and the
same requirements apply to the robust estimator
for SUR. The simulation study also finds that the
performance of these methods does not improve in
CRTs with more individuals per cluster.
Grieve and others25 proposed a flexible Bayesian
hierarchical model to tackle the main statistical
issues faced by CEAs of CRTs. However, such mod-
els are complex to implement, and other more acces-
sible MLMs may be required to improve practice.
Our simulation showed that a MLM estimated by
maximum likelihood, assuming a bivariate normal
distribution for costs and outcomes, can perform
well even when costs are highly skewed. Although
Table 4 Bias, rMSE, CI Coverage, and Width of the Mean INB for the Final Case (True INB = £1000)
SUR
GEE
TSB
MLMWithout
Robust SE
With
Robust SE
With
Robust SE
Without Shrinkage
Correction
With Shrinkage
Correction ML
Mean bias (SE) 6.63 (4.40) 6.63 (4.41) 6.63 (4.40) 7.10 (4.38) 6.85 (4.38) 7.95 (4.33)
rMSE 197 197 197 196 196 194
CI coverage 0.858 0.921 0.920 0.978 0.944 0.938
Mean CI width 583 726 724 924 778 754
Lower tail error rate 0.072 0.041 0.041 0.014 0.029 0.033
Upper tail error rate 0.120 0.038 0.039 0.010 0.028 0.030
Note: INB = incremental net benefit; SUR = seemingly unrelated regression; GEE = generalized estimating equation; TSB = nonparametric 2-stage boot-
strap; MLM = multilevel model; SE = standard error; ML = maximum likelihood; rMSE = root mean squared error; CI = confidence interval.
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in a different context, this corroborates previous
findings that suggest methods assuming normality
may be quite robust to skewed cost data.21,40,41,43
However, it would be worth investigating whether
MLMs that better accommodate skewed costs would
lead to gains in precision.
This study has several limitations. While the sim-
ulation considers a wide range of circumstances and
the case study provides a useful illustration, in prac-
tice, some CEAs face further complications. If, for
example, there are baseline imbalances between
the treatment groups, or cost-effectiveness estimates
are required for particular subgroups, the methods
would need to consider covariates. The effects of
baseline covariates, and indeed treatment group,
on costs and outcomes may be multiplicative, not
additive.59 Also, CEAs may have more complex var-
iance structures than those considered.25,60 These
methods have not been tested under such circum-
stances, but MLMs may have more scope for adapta-
tion to these broader settings than the other
methods.18,20,21,43 In addition, we have not consid-
ered censored or missing data or combining CRT
data with evidence from other sources in decision
models. These are all avenues for further research.
In conclusion, CEAs of CRTs may inform recom-
mendations on the provision of area-level or public
health interventions. This study finds that MLMs
and TSB (with correction) are appropriate analytical
methods for CEAs of CRTs across a wide range of cir-
cumstances. While methods that use a robust vari-
ance estimator such as SUR and the GEE model
considered here are simple to implement, they are
not recommended for CEAs of CRTs with few (less
than 10) clusters in each treatment arm.
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